The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients
Open accessAbstract
Background Standardized conditions to distinguish subpopulations of colorectal cancer (CRC) patients more and less sensitive to cetuximab therapy remain undefined.Materials and methods We retrospectively analyzed epidermal growth factor receptor (EGFR) copy number by fluorescence in situ hybridization (FISH) in paraffin-embedded tumor blocks from 85 chemorefractory CRC patients treated with cetuximab. Results were analyzed according to different score systems previously reported in colorectal and lung cancers. The primary end point of the study was identification of the EGFR FISH score that best associates with response rate (RR).Results Using receiver operating characteristic (ROC) analysis, the cut-off that best discriminated responders versus nonresponders to cetuximab was a mean of 2.92 EGFR gene copies per cell. This model showed sensitivity of 58.6% [95% confidence interval (CI) = 47.1-70.1) and specificity of 93.3% (95% CI = 80.6-100). EGFR FISH-positive patients (N = 43, 50.6%) had significantly higher RR (P = 0.0001) and significantly longer time to disease progression (P = 0.02) than EGFR FISH negative (N = 42, 49.4%). Other scoring systems resulted less accurate in discriminating patients with the highest likelihood of response to cetuximab therapy.Conclusions CRC patients with high EGFR gene copy number have an increased likelihood to respond to cetuximab therapy. Prospective clinical trials with a careful standardization of assay conditions and pattern interpretation are urgently needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Increased EGFR gene copy number could predict response among KRAS wild-type patients [53, 91, 111-113]”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [113]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Hapeman, D. E., & Agresti, A. (1991) · Technometrics · doi:10.1080/00401706.1991.10484817 · Cited by 9,407
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citationJemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R. K., Raben, D., Jassem, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053422 · Cited by 5,109
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Self-citation
Cited by
Sorted by citations
Items 201–267 of 267
Vecchione, L., Saridaki, Z., & Tejpar, S. (2011) · Current Colorectal Cancer Reports · doi:10.1007/s11888-011-0112-3 · Cited by 4
High-Grade Salivary Gland Ductal Carcinoma With Unusual EGFR Amplification Responsive to Afatinib
Lai, J., Reddy, A. K., Newberg, J. Y., Montesion, M., & Chang, P. M. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00186 · Cited by 4
Review on EGFR-ERK1/2 signaling cascade: implications on cell proliferation in health and disease
Fetoh, M. E. A., Abdel‐Fattah, M. M., Afify, H., Ramadan, L. A. A., & Mohamed, W. R. (2023) · Egyptian Pharmaceutical Journal · doi:10.4103/epj.epj_52_23 · Cited by 4
Safety and Efficacy of Panitumumab in the Treatment of Metastatic Colorectal Cancer
Freeman, D. J. (2009) · Clinical Medicine Therapeutics · doi:10.4137/cmt.s2039 · Cited by 4
What can molecular pathology offer for optimal decision making?
Aust, D. E., Sommer, U., & Baretton, G. B. (2012) · Annals of Oncology · doi:10.1093/annonc/mds346 · Cited by 4
Takano, T., Ota, S., Hori, A., Seki, N., & Eguchi, K. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0105 · Cited by 4
Immunotherapy for precision medicine in colorectal cancer
Cao, M., Xu, M. Y., Bairmani, Z. A., Bashir, B., Waldman, S. A., & Snook, A. E. (2025) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2025.2560303 · Cited by 3
Dynamic Regulation of Adherens Junctions: Implication in Cell Differentiation and Tumor Development
Pelissier-Rota, M. A., Chartier, N. T., & Jacquier‐Sarlin, M. R. (2015) · Springer eBooks · doi:10.1007/978-94-017-7380-5_4 · Cited by 3
Haque, S., Morton, D. G., & Welch, H. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.05.003 · Cited by 3
Roles of pathologists in molecular targeted cancer therapy
OSAMURA, R. Y. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00960.x · Cited by 3
Lièvre, A., & Laurent‐Puig, P. (2009) · Personalized Medicine · doi:10.2217/17410541.6.2.145 · Cited by 3
Implications of KRAS mutation status for the treatment of metastatic colorectal cancer
Ciardiello, F., Tejpar, S., & Papamichael, D. (2009) · Targeted Oncology · doi:10.1007/s11523-009-0129-6 · Cited by 4
Self-citationGrimstein, C., & Bai, J. P. F. (2011) · Therapeutic Delivery · doi:10.4155/tde.10.101 · Cited by 3
EGFR gene copy number decreases during anti-EGFR antibody therapy in colorectal cancer
Birkman, E., Avoranta, T., Ålgars, A., Korkeila, E. A., Lintunen, M., Lahtinen, L., Kuopio, T., Ristamäki, R., Carpén, O., & Sundström, J. T. T. (2018) · Human Pathology · doi:10.1016/j.humpath.2018.07.028 · Cited by 4
Hirsch, F. R., Herbst, R. S., Olsen, C. C., Chansky, K., Crowley, J. J., Kelly, K. L., Franklin, W. A., Bunn, P. A., Varella‐Garcia, M., & Gandara, D. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0873 · Cited by 3
Self-citationMolecular Pathology of Gastrointestinal Cancer
Yantiss, R. K., & Samowitz, W. S. (2012) · Surgical pathology clinics · doi:10.1016/j.path.2012.08.002 · Cited by 2
Moroni, M., Veronese, S. M., Bianchi, A. S., Artale, S. A., & Siena, S. (2008) · Targeted Oncology · doi:10.1007/s11523-008-0073-x · Cited by 2
Predicting cetuximab efficacy in patients with advanced colorectal cancer
Garrett, C. H., & Şahin, İ. H. (2014) · Current Biomarker Findings · doi:10.2147/cbf.s54310 · Cited by 2
Can we predict the response to epidermal growth factor receptor targeted therapy?
Manegold, P. C., Lurje, G., Pohl, A., Ning, Y., Zhang, W., & Lenz, H. (2008) · Targeted Oncology · doi:10.1007/s11523-008-0077-6 · Cited by 2
Guide to Targeted Therapies: EGFR mutations in NSCLC
Cappuzzo, F. (2014) · Springer eBooks · doi:10.1007/978-3-319-03059-3 · Cited by 3
Self-citationMolecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab
Ma, Z., Lei, C., & Hu, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821584-5.00007-9 · Cited by 2
Cancer colorectal métastatique et thérapies ciblées
Fiore, F. D., oden-Gangloff, A., & Michel, P. (2009) · Côlon & Rectum · doi:10.1007/s11725-009-0185-1 · Cited by 2
Matthews, D. J., & Gerritsen, M. E. (2010) · Wiley eBooks · doi:10.1002/9780470555293.ch8 · Cited by 2
Resistance to EGFR Inhibitors in NSCLC: Mechanistic Insights and Emerging Therapies
Khoury, R., Raffoul, C., Hanna, C., Saleh, K., Shayya, A., Nahouli, M., & Ghanem, H. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27125197 · Cited by 2
Molecular biomarker profile of EGFR copy number, KRAS and BRAF mutations in colorectal carcinoma
Rong, R., Tull, J., & Zhang, S. (2012) · Journal of Solid Tumors · doi:10.5430/jst.v2n4p27 · Cited by 1
Karapetis, C. S., & Price, T. J. (2012) · Colorectal Cancer · doi:10.2217/crc.12.14 · Cited by 1
Mechanisms of acquired resistance to anti-EGF receptor treatment in colorectal cancer
Montagut, C. O., & Albanell, J. (2012) · Colorectal Cancer · doi:10.2217/crc.12.62 · Cited by 1
Napolitano, T. T. S. (2014) · Journal of Carcinogenesis & Mutagenesis · doi:10.4172/2157-2518.s10-001
Markers of Sensitivity and Resistance to EGFR Inhibitors in Colorectal Cancer
Monzon, J. G., & Dancey, J. E. (2020) · doi:10.1201/9781003159469-7 · Cited by 1
Stratifying Cancer Therapies by Molecular Interactions and Imaging
Galazi, M., Weitsman, G. E., Monypenny, J., Coban, O., Milewicz, H., Gómez, V., Ciccarelli, F. D., & Ng, T. (2017) · Springer eBooks · doi:10.1007/978-3-319-53661-3_15 · Cited by 1
Therapeutic Drug Monitoring of Selected Anticancer Drugs
Milone, M. C. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-385467-4.00014-2 · Cited by 2
Santos, V. S., Lago, N. M., García, C. P., García, A. P., & Aparicio, L. M. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-90055-3.00043-0 · Cited by 1
Markers of Sensitivity and Resistance to EGFR Inhibitors in Colorectal Cancer
Monzon, J. G., & Dancey, J. E. (2013) · Pan Stanford Publishing eBooks · doi:10.1201/b15029-8 · Cited by 1
Sporadische Tumoren des Kolorektums
Aust, D. E., & Baretton, G. B. (2013) · Springer eBooks · doi:10.1007/978-3-642-02322-4_28 · Cited by 2
EGFR et cancers colorectaux : quoi de neuf ?
Sabourin, J., & Bibeau, F. (2007) · Annales de Pathologie · doi:10.1016/s0242-6498(07)78272-x · Cited by 1
Moroni, M., Marrapese, G., & Veronese, S. M. (2009) · Oncology Reviews · doi:10.1007/s12156-009-0017-4 · Cited by 1
Personalized management for colorectal cancer
Custodio, A., & Feliú, J. (2011) · doi:10.2217/ebo.11.168 · Cited by 1
Pharmacogenetics in Colorectal Cancer
Ferraldeschi, R. (2010) · Springer eBooks · doi:10.1007/978-90-481-8618-1_5
Advances in Management of Metastatic Colorectal Cancer
Wang‐Gillam, A., Lockhart, A. C., & Picus, J. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511976117.035
A cohort study of sex differences and prognostic biomarkers in colorectal cancer
Wangefjord, S. (2013) · Lund University Publications (Lund University)
Balko, J. M. (2009) · UKnowledge (University of Kentucky)
Marqueurs moléculaires prédictifs de réponse aux thérapies ciblées dans les cancers digestifs
Perkins, G. (2012) · theses.fr (ABES) · doi:10.70675/5b4631efzc0e5z4dddz8408z43ab410793f3
The Clinical Role of Cetuximab in the Management of Non-Small-Cell Lung Cancer
Ibrahim, E. M., Alfayea, T. M., & Kazkaz, G. A. (2012) · Lung Cancer Management · doi:10.2217/lmt.12.8
Predicting the response to targeted therapy in metastatic colorectal cancer
Azad, A., & Tebbutt, N. C. (2008) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/j.1743-7563.2008.00215.x
Chomy, F. (2009) · Revue de Pneumologie Clinique · doi:10.1016/s0761-8417(09)73451-0
Thérapies ciblées dans le traitement des cancers colorectaux métastatiques : place actuelle
Cacheux, W., Tourneau, C. L., Baranger, B., Mignot, L., & Mariani, P. (2011) · Journal de Chirurgie Viscérale · doi:10.1016/j.jchirv.2010.12.007
Predictive markers of cetuximab efficacy in metastatic colorectal cancer
Khambata‐Ford, S., Harbison, C. T., & Mauro, D. J. (2008) · Current Colorectal Cancer Reports · doi:10.1007/s11888-008-0030-1
Predictive markers for anti-EGFR antibodies in colorectal cancer: the beginning of a new era
Cutsem, E. V., & Tejpar, S. (2008) · Targeted Oncology · doi:10.1007/s11523-008-0097-2
Troiani, T., Venturini, F., Napolitano, S., Martini, G., Gambardella, V., Ciardiello, F., & Martinelli, E. (2014) · Colorectal Cancer · doi:10.2217/crc.14.17
Self-citationRelating Biomarkers to Efficacy and The Efficacy Curve: A Review of Egfr Therapies in Oncology
Stroupe, S. D., & Colpitts, T. L. (2009) · Personalized Medicine · doi:10.2217/pme.09.70
Targeted Therapies For Intestinal Tumorigenesis
Chiorean, E. G., Coveler, A. L., Grim, J. E., & Grady, W. M. (2015) · Springer eBooks · doi:10.1007/978-3-319-19986-3_13
Moro‐Sibilot, D., Duruisseaux, M., Levra, M. G., Sakhri, L., & Toffart, A. (2015) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(16)30033-7
Ålgars, A. (2012) · UTUPub (University of Turku)
number in 101 advanced colorectal cancer patients treated with chemotherapy plus cetuximab
Campanella, C., Mottolese, M., Cianciulli, A. M., Torsello, A., Merola, R., Sperduti, I., Melucci, E., Conti, S., Diodoro, G., Zeuli, M., et al. (2010)
RAS and RAF mutation status in the selection of patients for anti-EGFR therapy
Mulet-Margalef, N., Doménech, M., & Salazar, R. (2016) · Colorectal Cancer · doi:10.2217/crc-2015-0013
Advances in personalized cancer management
Roukos, D. H. (2011) · doi:10.2217/9781780840680
Molecular determinants of therapeutic response to targeted therapies in metastatic colorectal cancer
Weickhardt, A. J. (2011) · Minerva Access (University of Melbourne)
EGFR-Targeted Therapies in Non-small Cell Lung Cancer
Cappuzzo, F. (2014) · Springer eBooks · doi:10.1007/978-3-319-03059-3_5
Self-citationRied, T., Heselmeyer‐Haddad, K., Camps, J., & Gaiser, T. (2016) · Springer eBooks · doi:10.1007/978-1-59745-458-2_4
Church, D. N., Midgley, R. S., & Kerr, R. S. (2012) · Humana Press eBooks · doi:10.1007/978-1-61779-615-9_9 · Cited by 1
Therapeutic drug monitoring of selected anticancer drugs
Milone, M. C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18649-3.00022-7
Lineage and Molecular Marker Integration in Diagnosis and Differential Diagnosis of Neck Tumors
El‐Naggar, A. K. (2024) · Springer eBooks · doi:10.1007/978-3-031-67675-8_9
Clinical Characteristics of and Treatment Pattern for EGFR-Amplified Colorectal Cancer
Kim, S.-E., Jeong, H., Kim, J. E., Kim, D., Hong, Y. S., Kim, D., Kim, T., Lee, J. S., & Kim, T. W. (2025) · Cancer Research and Treatment · doi:10.4143/crt.2024.569
Fernández, A. M. (2014) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Alvarez, R. S., Gottier, C., Montalban‐Arques, A., Bircher, A., Pöhlmann, D., Schwarzfischer, M., Mueller, A., Lang, S., Spalinger, M. R., & Scharl, M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177955
Autres biomarqueurs potentiels des anti-EGFR
Fiore, F. D., & Michel, P. (2013) · Springer eBooks · doi:10.1007/978-2-8178-0527-6_13
Introducción de Cetuximab en el tratamiento del carcinoma escamoso de cabeza y cuello
Mesı́a, R. (2014) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Metadata
- Authors
- Cappuzzo, F., Finocchiaro, G., Rossi, E., Jänne, P. A., Carnaghi, C., Calandri, C., Bencardino, K., Ligorio, C., Ciardiello, F., Pressiani, T., Destro, A., Roncalli, M., Crino, L., Franklin, W. A., Santoro, A., & Varella-Garcia, M.
- Affiliations
- IRCCS Humanitas Research Hospital (IT)
- University of Colorado Cancer Center (US)
- Ospedale Bellaria (IT)
- Policlinico San Matteo Fondazione (IT)
- University of Campania "Luigi Vanvitelli" (IT)
- Corresponding author
- Cappuzzo, F.
- ORCID
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2008-04
- Volume
- 19
- Issue
- 4
- Pages
- 717-723
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2158475201
- Cited by
- 267
- References
- 39
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 3 · 2023: 2 · 2022: 2 · 2021: 5 · 2020: 4 · 2019: 5 · 2018: 5 · 2017: 6 · 2016: 8 · 2015: 12 · 2014: 18 · 2013: 20 · 2012: 24
- FWCI
- 18.73
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Annals of Oncology (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Università degli Studi di Napoli Federico II
- Cancer Center, University of Colorado
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- EGFR copy number, cetuximab, colorectal cancer, chemorefractory cancer, predictive biomarkers, treatment response prediction, time to progression, EGFR amplification
- MeSH terms
- Cetuximab, Adult, Aged, Antibodies, Monoclonal, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Immunohistochemistry, Italy, Male, Middle Aged, Predictive Value of Tests, Retrospective Studies, ROC Curve, Sensitivity and Specificity, Biomarkers, Tumor, Colorectal Neoplasms, Confidence Intervals, Survival Analysis, Treatment Outcome, In Situ Hybridization, Fluorescence, Disease-Free Survival, Patient Selection, Drug Resistance, Neoplasm, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
